Halozyme Therapeutics Inc (HALO)

Apr 01, 2025

Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock - Investing.com India

Apr 01, 2025

Apr 01, 2025

Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock By Investing.com - Investing.com UK

Apr 01, 2025

Apr 01, 2025

4,812 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by EntryPoint Capital LLC - MarketBeat

Apr 01, 2025

Mar 31, 2025

Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Mar 31, 2025

Mar 31, 2025

Long Term Trading Analysis for (HALO) - news.stocktradersdaily.com

Mar 31, 2025

Mar 31, 2025

Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method - Nasdaq

Mar 31, 2025

Mar 31, 2025

Major Breakthrough: New Cancer Drug Delivery Method Gets EU Panel Support - Stock Titan

Mar 31, 2025

Mar 28, 2025

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025

Mar 27, 2025

Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters

Mar 27, 2025

Mar 27, 2025

Halozyme Therapeutics (HALO) Stock Price, News & Analysis - MarketBeat

Mar 27, 2025

Mar 24, 2025

Halozyme stock soars to all-time high of $65.54 By Investing.com - Investing.com South Africa

Mar 24, 2025

Mar 24, 2025

Halozyme stock soars to all-time high of $65.54 - Investing.com India

Mar 24, 2025

Mar 24, 2025

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance

Mar 24, 2025

Mar 21, 2025

Halozyme Announces Retirement of Chief Technical Officer - TipRanks

Mar 21, 2025

Mar 21, 2025

Halozyme announces CTO retirement, effective immediately - Investing.com India

Mar 21, 2025

Mar 21, 2025

Halozyme announces CTO retirement, effective immediately By Investing.com - Investing.com Australia

Mar 21, 2025

Mar 21, 2025

Drug developers show mixed performance in early 2025 - BioWorld MedTech

Mar 21, 2025

Mar 21, 2025

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance

Mar 21, 2025

Mar 21, 2025

Halozyme Joins the $1 Billion Club - Yahoo Finance

Mar 21, 2025

Mar 17, 2025

AstraZeneca signs $1.35B Alteogen deal for subcutaneous cancer drugs - Fierce Pharma

Mar 17, 2025

Mar 14, 2025

Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha

Mar 14, 2025

Mar 14, 2025

Zacks Research Issues Negative Outlook for HALO Earnings - Defense World

Mar 14, 2025

Mar 13, 2025

Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why - MSN

Mar 13, 2025

Mar 13, 2025

Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue - MSN

Mar 13, 2025

Mar 13, 2025

Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Mar 13, 2025

Mar 12, 2025

Smartleaf Asset Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World

Mar 12, 2025

Mar 11, 2025

HALO vs. AMGN: Which Stock Is the Better Value Option? - Yahoo Finance

Mar 11, 2025

Mar 11, 2025

Charles Schwab Investment Management Inc. Buys 9,780 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World

Mar 11, 2025

Mar 10, 2025

Insider Sell: Jeffrey Henderson Sells 5,000 Shares of Halozyme T - GuruFocus.com

Mar 10, 2025

Mar 10, 2025

New version of Merck's Keytruda faces possible patent battle, WSJ reports - MSN

Mar 10, 2025

Mar 10, 2025

Halozyme Therapeutics' (HALO) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Mar 10, 2025

Mar 08, 2025

Halozyme Therapeutics (NASDAQ:HALO) Earns Buy Rating from HC Wainwright - Defense World

Mar 08, 2025

Mar 07, 2025

Merck set for patent battle with Halozyme over injectable Keytruda: WSJ - MSN

Mar 07, 2025

Mar 07, 2025

Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 07, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Mar 07, 2025

Mar 07, 2025

H.C. Wainwright maintains Halozyme stock Buy rating, $72 target By Investing.com - Investing.com Canada

Mar 07, 2025

Mar 06, 2025

High Growth Tech Stocks To Watch In US March 2025 - Yahoo Finance

Mar 06, 2025

Mar 06, 2025

JMP maintains Halozyme stock $78 target amid Merck challenge - Investing.com India

Mar 06, 2025

Mar 06, 2025

In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight - Fierce Pharma

Mar 06, 2025

Mar 05, 2025

Exclusive | New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle - The Wall Street Journal

Mar 05, 2025

Mar 05, 2025

Patent clash looms over Merck & Co.'s subcutaneous Keytruda - FirstWord Pharma

Mar 05, 2025

Mar 05, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance

Mar 05, 2025

Mar 05, 2025

Merck, Halozyme in patent battle over new Keytruda (MRK:NYSE) - Seeking Alpha

Mar 05, 2025

Mar 04, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Mar 04, 2025

Mar 03, 2025

Halozyme director Jeffrey Henderson sells shares worth $293,458 - Investing.com India

Mar 03, 2025

Mar 03, 2025

Halozyme Therapeutics Director Sells 5,000 Shares - TradingView

Mar 03, 2025

Mar 03, 2025

Director Henderson Jeffrey William sold $293,458 worth of shares (5,000 units at $58.69), decreasing direct ownership by 13% to 33,611 units (SEC Form 4) - Quantisnow

Mar 03, 2025

Mar 01, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Trimmed by Principal Financial Group Inc. - MarketBeat

Mar 01, 2025